Skip to main content
Clinical Trials/NCT06166459
NCT06166459
Not yet recruiting
Not Applicable

Drug-coated Balloon Combined With Provisional Drug-eluting Stent Implantation (Yao Strategy) for the Treatment of de Novo Medina 0,1,0 or 0,0,1 Bifurcation Lesion

Xuzhou Third People's Hospital0 sites200 target enrollmentApril 22, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Xuzhou Third People's Hospital
Enrollment
200
Primary Endpoint
major adverse cardiovascular events
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Percutaneous coronary intervention for coronary bifurcation lesions represents one of the most challenging procedures in interventional cardiology because of lower angiographic success rate and increased risk of procedural complications. The study is designed to enroll 200 patients with acute or chronic coronary syndromes that meet the indications for intervention and with angiographic confirmed de novo Medina type 0,1,0 or 0,0,1 bifurcation lesion. In view of the potential risks of using DCB alone in the treatment of de novo bifurcation lesions, the following 2 treatment strategies are available. (1) DCB combined with provisional DES implantation 1-2 mm distally to the lesion ostium whenever this was required (DCB+pDES strategy). (2) DES implantation 1-2 mm distally to the lesion ostium followed by DCB (DES+DCB strategy). The primary endpoint was late lumen loss and major adverse cardiovascular events.

Registry
clinicaltrials.gov
Start Date
April 22, 2024
End Date
March 1, 2026
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Xuzhou Third People's Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subjects at the age between ≥18 and ≤80 years old;
  • De novo native lesion, Median type 010/001 bifurcation lesion;
  • The reference diameter of the target vessel was 2.75-4.0mm and the length was less than 40mm;
  • Subjects are willing to participate in the study, sign informed consent form, and accept clinical follow-up.

Exclusion Criteria

  • The diameter stenosis of adjacent branch vessel ostium ≥50%;
  • Acute ST-segment elevation myocardial infarction;
  • Stents implanted within 10 mm proximal or distal to the target lesion;
  • Aneurysm within 10 mm proximal or distal to the target lesion;
  • There is target vessel distortion or severe calcification lesion, so balloon catheter fails to pass;
  • Previous coronary artery bypass grafting;
  • Evidence for extensive thrombus within target vessel;
  • Evidence of heart failure by at least one of the following: a. Most recent LVEF ≤35%, or b. Current heart failure defined as dyspnea at rest (NYHA class IV assessed day of procedure), or c. Killip class ≥2 (post STEMI patients);
  • Subjects with a life expectancy of ≤1 year;
  • Subjects with stroke, peptic ulcer, or gastrointestinal bleeding within the past 6 months;

Outcomes

Primary Outcomes

major adverse cardiovascular events

Time Frame: 1 year

include cardiac death, non-fatal myocardial infarction, and target lesion revascularization.

late lumen loss

Time Frame: 9 months follow-up

post-procedural minimum lumen diameter minus follow-up minimum lumen diameter.

Similar Trials